Comment
doi: 10.1183/13993003.02028-2019.
Print 2020 Jan.
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?
Affiliations
- PMID: 32001499
- DOI: 10.1183/13993003.02028-2019
Item in Clipboard
Comment
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?
Eur Respir J.
.
Free article
No abstract available
Conflict of interest statement
Authors contributions: All authors contributed equally to literature search, designing and writing of the manuscript. Conflict of interest: H. Slabbynck has nothing to disclose. Conflict of interest: J. Clukers has nothing to disclose. Conflict of interest: D. Galdermans has nothing to disclose.
Comment in
-
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?Eur Respir J. 2020 Jan 30;55(1):1902323. doi: 10.1183/13993003.02323-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 32001500 No abstract available.
Comment on
-
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).Eur Respir J. 2019 Oct 9;54(3):1901647. doi: 10.1183/13993003.01647-2019. Print 2019 Sep. Eur Respir J. 2019. PMID: 31473594 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
